# US 2013/0156722 A1 · Polymeric drug delivery conjugates and methods of making and using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156722 A1
- Document ID: US20130156722A1
- Status: Published application
- Kind: A1
- Application number: 13/583,270
- Filed: 2011-03-07
- Published: 2013-06-20
- Earliest claimed: 2010-03-08
- Assignees: University of Utah Research Foundation
- Inventors: Pavla Kopecková; Huaizhong Pan; Jiyuan Yang; Jindrich Kopecek; Kui Luo
- Web page: https://patentgrep.com/patent/US20130156722A1

## CPC

- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are biodegradable drug delivery conjugates for effectively delivering bioactive agents to a subject. The drug delivery conjugates comprise a water-soluble high molecular weight linear biodegradable polymer backbone comprising a plurality of linear water-soluble polymeric segments connected to one another by a first (main-chain) cleavable linker, wherein a bioactive agent is covalently bonded to at least one water-soluble polymeric segment, at least one cleavable linker, or a combination thereof. The conjugates possess numerous advantages over prior art delivery conjugates. Also described herein are methods for making and using the conjugates.

## Claims

### Claim 1

A drug delivery conjugate or the pharmaceutically acceptable salt or ester thereof comprising a water-soluble high molecular weight linear biodegradable polymer backbone comprising a plurality of linear water-soluble polymeric segments connected to one another by a first cleavable linker, wherein a bioactive agent is covalently bonded to at least one water-soluble polymeric segment, at least one cleavable linker, or a combination thereof.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the conjugate has a molecular weight from 50 kDa to 750 kDa.

### Claim 3 (depends on 1)

The conjugate of claim 1, wherein the water-soluble polymeric segment has a molecular weight less than 40 kDa.

### Claim 4 (depends on 1)

The conjugate of claim 1, wherein the water-soluble polymeric segment comprises the polymerization product of one or more unsaturated water-soluble monomers.

### Claim 5 (depends on 4)

The conjugate of claim 4, wherein the unsaturated water soluble monomer comprises the formula I
wherein R1 is hydrogen or methyl;
X is O or NR2, wherein R2 is hydrogen or an alkyl group;
L is an alkyl group, an aryl group, or a cycloalkyl group; and
Y is a hydrophilic group.

### Claim 6 (depends on 5)

The conjugate of claim 5, wherein R1 is methyl, X is NH, and L is a C1-C5 methylene group.

### Claim 7 (depends on 6)

The conjugate of claim 6, wherein L is a methylene group, an ethylene group, or an isopropylene group.

### Claim 8 (depends on 4)

The conjugate of claim 4, wherein the hydrophilic group is a hydroxyl group, an amino group, a thiol group, a SO3H group, or a zwitterionic group.

### Claim 9 (depends on 4)

The conjugate of claim 4, wherein the water soluble monomer comprises an N-substituted methacrylamide, an N,N-disubstituted acrylamide, a hydrophilic ester of methacrylic or acrylic acid, an N-vinylpyrrolidone, an N-acryloylmorpholine, a sulfoethylmethacrylate, an acrylic acid, a methacrylic acid, or any combination thereof.

### Claim 10 (depends on 4)

The conjugate of claim 4, wherein the water soluble monomer comprises N-(2-hydroxypropyl)methacrylamide (HPMA), N-[3-(N′-dicarboxymethyl)aminopropyl]methacrylamide (DAMA), N-methacryloylglycylphenylalanylleucylglycine-aminomalonic acid (MA-GFLG-diCOOH), N-(3-aminopropyl)methacrylamide, or any combination thereof.

### Claim 11 (depends on 1)

The conjugate of claim 1, wherein the bioactive agent is linked to the water soluble polymeric segment via a second cleavable linker.

### Claim 12 (depends on 4, 5, 6, 7, 8, 9, 10, 11)

The conjugate of claim 11, wherein the water-soluble polymeric segment comprises the polymerization product of one or more unsaturated water-soluble monomers in any of claims 4-10 and a monomer comprising the formula II
wherein R1 is hydrogen or methyl;
X is O or NR2, wherein R2 is hydrogen or an alkyl group;
L1 is a second cleavable linker; and
Z is the bioactive agent.

### Claim 13 (depends on 1)

The conjugate of claim 1, wherein the first and second cleavable linker is cleaved by an enzyme, a change in pH, or a combination thereof.

### Claim 14 (depends on 1)

The conjugate of claim 1, wherein the first and second cleavable linker comprises a peptide having from 2 to 13 amino acid residues.

### Claim 15 (depends on 1)

The conjugate of claim 1, wherein the first and second cleavable linker is a peptide having the amino acid sequence SEQ ID NOS 1-22.

### Claim 16 (depends on 1)

The conjugate of claim 1, wherein the first linker has the formula III
-(AA1)-K-(AA2)- (III)
wherein AA1 and AA2 are the same or different amino acid sequence comprising up to six amino acids, and
K is lysine, ornithine, or a diamine.

### Claim 17 (depends on 1)

The conjugate of claim 1, wherein the first and second cleavable linker comprises a pH-sensitive linker.

### Claim 18 (depends on 17)

The conjugate of claim 17, wherein the pH-sensitive linker is a carboxyalkylmaleic linker or an ascorbic linker.

### Claim 19 (depends on 1)

The conjugate of claim 1, wherein when the bioactive agent is covalently bonded to the first cleavable linker, the bioactive agent is bonded to the cleavable linker via a coupling reaction.

### Claim 20 (depends on 1)

The conjugate of claim 1, wherein the bioactive agent comprises an anti-cancer drug.

### Claim 21 (depends on 1)

The conjugate of claim 1, wherein the bioactive agent comprises paclitaxel, docetaxel, gemcitabine, platinates (cis-platin, carboplatin, DACH-Pt), doxorubicin, geldanamycin, or 9-aminocamptothecin.

### Claim 22 (depends on 1)

The conjugate of claim 1, wherein two or more different bioactive agents are covalently bonded to the conjugate.

### Claim 23 (depends on 1)

The conjugate of claim 1, wherein a targeting group is covalently attached to the water-soluble polymeric segment, the first cleavable linker, or a combination thereof.

### Claim 24 (depends on 23)

The conjugate of claim 23, wherein the targeting group is an antibody, an antibody fragment, a saccharide, or an epitope binding peptide, or an aptamer.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the composition is an injectable composition comprising a sterile aqueous medium as the pharmaceutically acceptable carrier.

### Claim 27 (depends on 1)

A method for delivering a bioactive agent to a subject comprising administering the conjugate of claim 1 to the subject.

### Claim 28 (depends on 1)

The use of the conjugate of claim 1 as a delivery device for a bioactive agent.

### Claim 29 (depends on 1)

The conjugate of claim 1, wherein the water-soluble polymeric segments and the first cleavable linker are coupled to one another via an azide-alkyne reaction, thiol-ene reaction, oxidation reaction, or a Diels-Alder reaction.
